Fidarestat

Fidarestat
Names
	Preferred IUPAC name (2S,4S)-6-Fluoro-2′,5′-dioxo-2,3-dihydrospiro[[1]benzopyran-4,4′-imidazolidine]-2-carboxamide
	Other names (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide
Identifiers
CAS Number	136087-85-9 ; 105300-43-4 (non specific) ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL84446;
ChemSpider	140679;
KEGG	D01842;
PubChem CID	160024;
UNII	8SH8T1164U ;
CompTox Dashboard (EPA)	DTXSID4046654 ;
	InChI InChI=1S/C12H10FN3O4/c13-5-1-2-7-6(3-5)12(4-8(20-7)9(14)17)10(18)15-11(19)16-12/h1-3,8H,4H2,(H2,14,17)(H2,15,16,18,19)/t8-,12-/m0/s1 Key: WAAPEIZFCHNLKK-UFBFGSQYSA-N;
	SMILES c1cc2c(cc1F)[C@@]3(C[C@H](O2)C(=O)N)C(=O)NC(=O)N3;
Properties
Chemical formula	C12H10FN3O4
Molar mass	279.227 g·mol−1
Melting point	290–300 °C (554–572 °F; 563–573 K)
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Fidarestat (SNK-860) is an aldose reductase inhibitor under investigation for treatment of diabetic neuropathy.

References

Aldose reductase inhibitor for treatment of diabetic complications. Prepn (stereo unspec): M. Kurono, et al., EP 193415; eidem, US 4740517 (1986, 1988 both to Sanwa)
Prepn of isomers: T. Yamaguchi et al., Arzneim.-Forsch. 44, 344 (1994)
Pharmacological profile: K. Mizuno et al. in Current Concepts of Aldose Reductase and Its Inhibitions, N. Sakamoto et al., Eds. (Elsevier, Amsterdam, 1990) pp 89–96.
Configuration and crystal structure of complex with aldose reductase: M. Oka et al., J. Med. Chem. 43, 2479 (2000).
Clinical efficacy in diabetic peripheral neuropathy: N. Hotta et al., Diabetes Care 24, 1776 (2001).
Clinical suppression of sorbitol accumulation in erythrocytes of diabetic patients: T. Asano et al., J. Diabetes Complications 16, 133 (2002); eidem, ibid. 18, 336 (2004).
Review of clinical development: N. Giannoukakis, Curr. Opin. Invest. Drugs 4, 1233-1239 (2003).